Epstein-Barr Virus Vaccine Research

The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a research study aimed at stopping the spread of the Epstein-Barr virus (EBV), the main cause of mono. Join our compensated study and further EBV vaccine research today!

Fast Facts

18 - 29 Years Old

Compensation Provided

Conducted in Bethesda, MD

About Our Research Study

Help researchers at the NIAID evaluate the safety and immune system response of a new Epstein-Barr virus vaccine. This research could help reduce future cases of mono.
 

Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.

Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.

Help researchers at the NIAID evaluate the safety and immune system response of a new Epstein-Barr virus vaccine. This research could help reduce future cases of mono.
 

Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.

Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.

Additional Information

The purpose of this research study is to determine the safety and immunogenicity of an EBV vaccine. Participation in this research study may inform future treatments used to prevent EBV, mono, and certain EBV-related cancers.

You may qualify for this study if you meet the following criteria.

Eligibility Criteria:

  • 18 – 29 years old
  • In general good health (no major medical conditions)
  • No ongoing use of immunosuppressive medications
  • No substance use disorder

Once enrolled, this study involves:

  • In-person and virtual visits
  • 3 doses of experimental EBV vaccine
  • Participant safety evaluation and monitoring

Compensation up to $2220 is provided for your time.

There is no cost for you to participate in our research study.